Nodal Counts on MDCT as a Surrogate Marker for Surgical Curability in Gastric Cancer
详细信息 查看全文
- 作者：Tsutomu Kawaguchi MD (1)
Shuhei Komatsu MD (1)
Daisuke Ichikawa MD (1)
Kazuma Okamoto MD (1)
Atsushi Shiozaki MD (1)
Hitoshi Fujiwara MD (1)
Yasutoshi Murayama MD (1)
Yoshiaki Kuriu MD (1)
Hisashi Ikoma MD (1)
Masayoshi Nakanishi MD (1)
Toshiya Ochiai MD (1)
Yukihito Kokuba MD (1)
Tsunehiko Nishimura MD (2)
Eigo Otsuji MD (1) - 刊名：Annals of Surgical Oncology
- 出版年：2012
- 出版时间：August 2012
- 年：2012
- 卷：19
- 期：8
- 页码：2465-2470
- 全文大小：245KB
- 参考文献：1. Aida K, Yoshikawa H, Mochizuki C, et al. Clinicopathological features of gastric cancer detected by endoscopy as part of annual health checkup. / J Gastroenterol Hepatol. 2008;23:632-. CrossRef
2. Otsuji E, Yamaguchi T, Sawai K, Okamoto K, Takahashi T. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. / Br J Cancer. 1999;79:1789-3. CrossRef
3. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. / Lancet Oncol. 2010;11:439-9. CrossRef
4. Pan Z, Zhang H, Yan C, et al. Determining gastric cancer resectability by dynamic MDCT. / Eur Radiol. 2010;20:613-0. CrossRef
5. Shinohara T, Ohyama S, Yamaguchi T, et al. Clinical value of multidetector row computed tomography in detecting lymph node metastasis of early gastric cancer. / Eur J Surg Oncol. 2005;31:743-. CrossRef
6. Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT—correlation with surgical and histopathologic result. / Radiology. 2007;242:472-2. CrossRef
7. Yan C, Zhu ZG, Yan M, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. / J Surg Oncol. 2009;100:205-4. CrossRef
8. Yanagita S, Natsugoe S, Uenosono Y, et al. Morphological distribution of metastatic foci in sentinel lymph nodes with gastric cancer. / Ann Surg Oncol. 2008;15:770-. CrossRef
9. Kim JJ, Song KY, Hur H, Hur JI, Park SM, Park CH. Lymph node micrometastasis in node-negative early gastric cancer. / Eur J Surg Oncol. 2009;35:409-4. CrossRef
10. Kawaguchi T, Ichikawa D, Komatsu S, et al. Clinical evaluation of JCGC and TNM staging on multidetector-row computed tomography in preoperative nodal staging of gastric cancer. / Hepatogastroenterology. 2011;58:838-1.
11. Katai H, Yoshimura K, Maruyama K, Sasako M, Sano T. Evaluation of the new International Union Against Cancer TNM staging for gastric carcinoma. / Cancer. 2000;88:1796-00. CrossRef
12. Yoo CH, Noh SH, Kim YI, Min JS. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. / World J Surg. 1999;23:492-. CrossRef
13. Ichikawa D, Kurioka H, Ueshima Y, et al. Prognostic value of lymph node staging in gastric cancer. / Hepatogastroenterology. 2003;50:301-.
14. Deng J, Liang H, Sun D, Wang D, Pan Y. Suitability of 7th UICC N stage for predicting the overall survival of gastric cancer patients after curative resection in China. / Ann Surg Oncol. 2010;17:1259-6. CrossRef
15. Sobin LH, Gospodarowicz MK, Wittekind C; International Union Against Cancer. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009. p. 73-.
16. Fukuya T, Honda H, Hayashi T, et al. Lymph-node metastases: efficacy of detection with helical CT in patients with gastric cancer. / Radiology. 1995;197:705-1.
17. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. / Gastric Cancer. 2009;12:6-2. CrossRef
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 14th ed. March 2010.
19. Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. / Br J Surg. 2009;96:1015-2. CrossRef
20. Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. / J Gastrointest Surg. 2002;6:212-3. CrossRef - 作者单位：Tsutomu Kawaguchi MD (1)
Shuhei Komatsu MD (1)
Daisuke Ichikawa MD (1)
Kazuma Okamoto MD (1)
Atsushi Shiozaki MD (1)
Hitoshi Fujiwara MD (1)
Yasutoshi Murayama MD (1)
Yoshiaki Kuriu MD (1)
Hisashi Ikoma MD (1)
Masayoshi Nakanishi MD (1)
Toshiya Ochiai MD (1)
Yukihito Kokuba MD (1)
Tsunehiko Nishimura MD (2)
Eigo Otsuji MD (1)
1. Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
2. Division of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan
文摘
Background Thin-slice multidetector row computed tomography (MDCT) has emerged as a promising diagnostic modality in various cancers. This study was designed to evaluate the utility of metastatic nodal counts on MDCT as a surrogate maker for surgical curability in gastric cancer. Methods Between 2005 and 2007, a total of 92 patients with gastric cancer underwent preoperative MDCT at a slice thickness of 1.0?mm at our hospital. All regional lymph nodes showing metastatic involvement were preoperatively counted. Results Although the total counts of metastatic lymph nodes on MDCT were significantly smaller than those found by histopathology (P?=?0.00001), there was a significant correlation between nodal counts on MDCT and histopathology by Spearman’s analysis [P?<?0.0001, pathologic counts?=?1.63x (counts on MDCT)?+?2.5]. Nodal counts on MDCT of?? were analyzed as putative pathologic nodal counts of?? by the equation, and pathologic metastatic nodal counts of?? were most significantly correlated with noncurative resection (P?<?0.0001). According to the logistic regression analysis, nodal counts on MDCT of?? were a significant independent variable for noncurative resection (P?=?0.0052, odds ratio 26.68). Nodal counts on MDCT of?? could distinguish noncurative patients from curative patients with 94.4% sensitivity and 71.6% specificity. Conclusions Nodal counts on MDCT could be a reliable surrogate maker for surgical curability of gastric cancer. This marker might enable us to select prospective candidates for additional or alternative treatments in gastric cancer.